FDA Grants Fast Track Designation to Investigational Narcolepsy Treatment
The oral orexin 2 receptor agonist currently in phase 1b development for patients with narcolepsy.
Category: Hypersomnias
Hypersomnias
Latest
Hypersomnias
Latest
Fatigue Emerges as Major Unmet Need in Hypersomnia Disorders
Survey findings suggest fatigue remains widespread and debilitating across narcolepsy and idiopathic hypersomnia, even among patients taking medications.
Hypersomnias
Latest
Gut Microbiota Imbalance Linked to Narcolepsy, Other Sleep Disorders
A new literature review synthesizes evidence connecting intestinal microbiome disruption to sleep disturbances, highlighting specific microbial biomarkers in narcolepsy and opening doors for targeted therapies.
Narcolepsy
Latest
Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders
The acquisition centers on Centessa’s pipeline of orexin receptor 2 agonists, including lead candidate cleminorexton, targeted for narcolepsy and idiopathic hypersomnia.
Idiopathic Hypersomnia
Latest
FDA Grants Orphan Drug Designation to IH Drug Contender
A phase 3 trial is underway to evaluate the drug's efficacy and safety in adults with IH, with enrollment expected to complete by the end of 2025.
Insufficient Sleep Syndrome
Latest
Sleep Disorders and Lack of Sleep Plague Active US Military Personnel
A new study found that 85% of active duty servicemen and servicewomen have sleep disorders.
Kleine-Levin Syndrome
Latest
Kleine-Levin Syndrome Foundation Taps First Executive Director
An experienced non-profit leader and author is appointed to the first-ever professional staff role for the foundation.